PubMed · 4725669
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
L L Greenlee. 1973. A multi-sample dialysis system.. https://doi.org/10.1016/0003-2697(73)90276-5
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Three new types of capillary coatings for capillary isoelectric focusing that avoid siloxane chemistry, resulting in hydrolytically stable coatings, are described and tested: phenyl-silica, acrylamide-reacted vinyl-silica, and pure PTFE. Capillaries of these three types were compared using standard proteins and a biological mixture of proteins similar to what might be encountered in actual use. Of these, the acrylamide-coated capillary produced the highest-quality results. In contrast to capillaries prepared using siloxane reactions, the capillaries described herein exhibited greatly enhanced stability at high pH.
Palytoxin (PTX), one of the most toxic nonprotein molecules known, is cytotoxic at picomolar concentrations against a wide variety of cell types. In contrast to most cytotoxins, PTX exerts its activity extracellularly. A method for targeting PTX to tumor cells is described in which a monoclonal antibody-enzyme conjugate activates a PTX prodrug at surfaces of tumor cells. The prodrug, N-(4'-hydroxyphenylacetyl)palytoxin (NHPAP), was prepared by reacting PTX with an active ester of 4-hydroxyphenylacetic acid. NHPAP was 1000 times less toxic than PTX to a panel of carcinoma and lymphoma cell lines. The cytotoxic activity of the combination of penicillin G amidase from Escherichia coli with NHPAP was equal to PTX. Two cell lines that were multidrug resistant showed no enhanced resistance to NHPAP +/- penicillin G amidase. Immunologically specific activation of NHPAP took place when H2981 cells (L6 antigen positive) were treated with the monoclonal antibody conjugate L6-penicillin G amidase followed by NHPAP. This system is distinguished from other prodrug activation schemes, since the released drug exerts its activity extracellularly, has high potency, and may be able to overcome the multidrug resistant phenotype.
Selective modulation of brain glutathione (GSH) may assist the elucidation of the role of GSH in the central nervous system. Subcutaneous administration of diethyl maleate (DEM) depleted both cerebral and hepatic GSH in a dose- and time-dependent manner. While hepatic GSH levels returned to control levels 6 hr after DEM administration, brain GSH levels remained significantly lowered for up to 12 hr after administration of DEM. However, intrathecal administration of DEM resulted in a selective lowering of brain GSH without altering hepatic levels. Intrathecal administration of L-buthionine sulfoximine (L-BSO; 1.0 mmol/kg body wt) also depleted the GSH content of the brain and the levels remained low 24 hr after L-BSO administration. The extent of GSH depletion varied in different regions of the brain; maximal depletion was observed in the brainstem, followed by the cerebellum, striatum, cortex and hippocampus. Intrathecal administration of L-2-oxothiazolidine 4-carboxylate (OTC) resulted in a marginal elevation of GSH levels in the brain. There was considerable regional variation. A maximal elevation of 134% was seen in the hippocampus, 6 hr following the intrathecal administration of 8.0 mmol of OTC/kg body wt. The effect of the modulation of brain GSH levels on acrylamide (ACR)-induced neurotoxicity was examined. Depletion of GSH by pretreatment of mice with L-BSO or DEM (administered intrathecally) enhanced the toxicity of ACR as measured by the inhibition of brain glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity. The inhibition of GAPDH by ACR was attenuated by pretreatment of animals with OTC. Thus, brain GSH may play an important role in the detoxification of xenobiotics, in situ within the central nervous system.